Tzu‐Min Yeh

3.8k total citations
38 papers, 513 citations indexed

About

Tzu‐Min Yeh is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Tzu‐Min Yeh has authored 38 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 18 papers in Hematology and 12 papers in Molecular Biology. Recurrent topics in Tzu‐Min Yeh's work include CAR-T cell therapy research (24 papers), Multiple Myeloma Research and Treatments (18 papers) and Protein Degradation and Inhibitors (12 papers). Tzu‐Min Yeh is often cited by papers focused on CAR-T cell therapy research (24 papers), Multiple Myeloma Research and Treatments (18 papers) and Protein Degradation and Inhibitors (12 papers). Tzu‐Min Yeh collaborates with scholars based in United States, Belgium and Germany. Tzu‐Min Yeh's co-authors include Saad Z. Usmani, Arnob Banerjee, Jesús G. Berdeja, Deepu Madduri, Sundar Jagannath, Enrique Zudaire, Scott Evans, Andrzej Jakubowiak, Jordan M. Schecter and Carolyn C. Jackson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tzu‐Min Yeh

36 papers receiving 501 citations

Peers

Tzu‐Min Yeh
Comparison fields: 5 of 61
  • Oncology 342
  • Molecular Biology 226
  • Hematology 224
  • Immunology 86
  • Biomedical Engineering 69
Replace Uri Greenbaum with:
Uri Greenbaum Israel
Jutta K. Neuenburg United States
Enrico Maffini Italy
Robin Sanderson United Kingdom
Gaoxiang Wang China
Oliver Van Oekelen United States
Wade Lovelace United States
Robert Offner Germany
Lena Oevermann Germany
Yaohui Wu China
Uri Greenbaum Israel View profile →
Citations per field, relative to Tzu‐Min Yeh
Tzu‐Min Yeh · 1×
Citations per year, relative to Tzu‐Min Yeh
Tzu‐Min Yeh · 1×

Countries citing papers authored by Tzu‐Min Yeh

Since Specialization
Citations

This map shows the geographic impact of Tzu‐Min Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tzu‐Min Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tzu‐Min Yeh more than expected).

Fields of papers citing papers by Tzu‐Min Yeh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tzu‐Min Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tzu‐Min Yeh. The network helps show where Tzu‐Min Yeh may publish in the future.

Co-authorship network of co-authors of Tzu‐Min Yeh

This figure shows the co-authorship network connecting the top 25 collaborators of Tzu‐Min Yeh. A scholar is included among the top collaborators of Tzu‐Min Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tzu‐Min Yeh. Tzu‐Min Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Yi Lin, Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Christopher del Corral, Lida Pacaud, Sundar Jagannath
1
2
P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Sundar Jagannath, (unknown), Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, (unknown), Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, (unknown), Lida Pacaud, Yi Lin
2
3
MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Yi Lin, (unknown), Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, (unknown), Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, (unknown), Lida Pacaud, Sundar Jagannath
0
4
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesús G. Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu‐Min Yeh, (unknown), Lida Pacaud, Muhammad Akram, Sundar Jagannath
6
5
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
2023 ·Journal of Clinical Oncology ·Yi Lin, Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, (unknown), Lida Bubuteishvili‐Pacaud, Sundar Jagannath
71
6
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
2022 ·Cancer Reports ·Rebecca Crawford, Katharine S. Gries, Satish Valluri, John Fastenau, Ross Morrison, Tzu‐Min Yeh, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, William Deraedt, Lynda Doward
7
7
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
2022 ·Cancer Science ·Masaki Ri, Kenshi Suzuki, Tadao Ishida, Junya Kuroda, Taku Tsukamoto, Takanori Teshima, Hideki Goto, Carolyn C. Jackson, (unknown), Lida Pacaud, (unknown), Tzu‐Min Yeh, (unknown), (unknown), (unknown), Shinsuke Iida
12
8
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
2022 ·Clinical Lymphoma Myeloma & Leukemia ·Katja Weisel, Amrita Krishnan, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Tzu‐Min Yeh, Arnob Banerjee, Fevzi Yalniz, Tonia Nesheiwat, Suzy Van Sanden, Joris Diels, Satish Valluri, Saad Z. Usmani, Jesús G. Berdeja, Sundar Jagannath, Tom Martin
10
9
Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
2022 ·Blood ·Nikhil C. Munshi, Bruno Paiva, Thomas G. Martin, Saad Z. Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu‐Min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús F. San Miguel
4
10
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
2022 ·Journal of Clinical Oncology ·Saad Z. Usmani, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Changwei Zhou, Lida Bubuteishvili‐Pacaud, Yi Lin, Sundar Jagannath
10
11
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
2021 ·Current Medical Research and Opinion ·Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Hong Tian, Tzu‐Min Yeh, Arnob Banerjee, Lida Pacaud, (unknown), (unknown), Chris Cameron, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo
34
12
Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
2021 ·Blood ·Yaël C. Cohen, Adam D. Cohen, Michel Delforge, Jens Hillengaß, Hartmut Goldschmidt, Katja Weisel, Marc‐Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu‐Min Yeh, Liwei Wang, Martin Vogel, (unknown), Muhammad Akram, Lida Pacaud, Tonia Nesheiwat, Mounzer Agha, Hermann Einsele
20
13
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
2021 ·Journal of Clinical Oncology ·Saad Z. Usmani, Jesús G. Berdeja, Deepu Madduri, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, Tzu‐Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Yi Lin, Thomas G. Martin, Sundar Jagannath
26
14
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
2019 ·Blood ·Deepu Madduri, Saad Z. Usmani, Sundar Jagannath, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Arnob Banerjee, Jeffrey L. Goldberg, Jordan M. Schecter, Sen Hong Zhuang, Jeffrey R. Infante, Syed Rizvi, Xiao-Hu Fan, Andrzej Jakubowiak, Jesús G. Berdeja
83
15
B-mode subwavelength vibration imaging
2017 ·2017 IEEE International Ultrasonics Symposium (IUS) ·Tzu‐Min Yeh, Menglin Li
1
16
Design considerations in clinical trials with cure rate survival data: A case study in oncology
2017 ·Pharmaceutical Statistics ·Steven Sun, Grace Liu, Tianmeng Lyu, (unknown), Tzu‐Min Yeh, Sudhakar Rao
4
17
Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211
2010 ·HIV Clinical Trials ·Tzu‐Min Yeh, Scott Evans, Roy M. Gulick, David B. Clifford
3
18
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087
2010 ·Journal of clinical lipidology ·Carl J. Fichtenbaum, Tzu‐Min Yeh, Scott Evans, Judith A. Aberg
28
19
Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals
2010 ·Journal of NeuroVirology ·Giovanni Schifitto, Lijuan Deng, Tzu‐Min Yeh, Scott Evans, Thomas Ernst, Jianhui Zhong, David B. Clifford
22
20
Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090
2007 ·HIV Clinical Trials ·Scott Evans, Tzu‐Min Yeh, Ned Sacktor, David B. Clifford, David M. Simpson, Eric N. Miller, Ronald J. Ellis, Victor Valcour, Christina M. Marra, Linda Millar, Giovanni Schifitto, (unknown)
25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uri Greenbaum Breakdown of academic impact, for papers by Jutta K. Neuenburg Breakdown of academic impact, for papers by Enrico Maffini Breakdown of academic impact, for papers by Robin Sanderson Breakdown of academic impact, for papers by Gaoxiang Wang Breakdown of academic impact, for papers by Oliver Van Oekelen Breakdown of academic impact, for papers by Wade Lovelace Breakdown of academic impact, for papers by Robert Offner Breakdown of academic impact, for papers by Lena Oevermann Breakdown of academic impact, for papers by Yaohui Wu
Rankless by CCL
2026